These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32440843)

  • 1. Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
    Gómez-Junyent J; Rigo-Bonnin R; Benavent E; Soldevila L; Padullés A; Cabo X; Tubau F; Ariza J; Murillo O
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):587-599. PubMed ID: 32440843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
    Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O
    J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.
    Ribera A; Soldevila L; Rigo-Bonnin R; Tubau F; Padullés A; Gómez-Junyent J; Ariza J; Murillo O
    Infection; 2018 Apr; 46(2):239-244. PubMed ID: 29363049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
    Moriyama B; Henning SA; Childs R; Holland SM; Anderson VL; Morris JC; Wilson WH; Drusano GL; Walsh TJ
    Ann Pharmacother; 2010 May; 44(5):929-35. PubMed ID: 20371747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
    Navarrete-Rouco ME; Luque S; Sorlí L; Benítez-Cano A; Roberts JA; Grau S
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):561-566. PubMed ID: 35657580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.
    Hachem RY; Chemaly RF; Ahmar CA; Jiang Y; Boktour MR; Rjaili GA; Bodey GP; Raad II
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1905-11. PubMed ID: 17387153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Lu Q; Luo R; Bodin L; Yang J; Zahr N; Aubry A; Golmard JL; Rouby JJ;
    Anesthesiology; 2012 Dec; 117(6):1335-47. PubMed ID: 23132092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
    Thabit AK; Hobbs ALV; Guzman OE; Shea KM
    Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.
    Naesens R; Vlieghe E; Verbrugghe W; Jorens P; Ieven M
    BMC Infect Dis; 2011 Nov; 11():317. PubMed ID: 22085766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant
    Sid Ahmed MA; Hamid JM; Husain AA; Hadi HA; Skariah S; Sultan AA; Ibrahim EB; Al Khal AL; Soderquist B; Jass J; Omrani AS
    Ann Med; 2021 Dec; 53(1):2345-2353. PubMed ID: 34882052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
    Fernandes M; Vira D; Medikonda R; Kumar N
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):315-22. PubMed ID: 26537122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J; Murillo O; Yu HH; Azad MAK; Wickremasinghe H; Rigo-Bonnin R; Benavent E; Ariza J; Li J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106246. PubMed ID: 33253904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.